Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Velocity Clinical Research (United States) · Yale University · +1 more institution
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
360
total citations
- FWCI
- 64.25
- Percentile
- 100%
- References
- 33
Citations per year
Authors
11Topics & keywords
Topics
Keywords
- Medicine
- Dulaglutide
- Placebo
- Type 2 diabetes
- Exenatide
- Metformin
- Internal medicine
- Glucagon-like peptide 1 receptor
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.